Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis
- 30 September 2019
- journal article
- review article
- Published by Springer Nature in Journal of Perinatology
- Vol. 39 (12) , 1584-1594
Abstract
Objective To systematically assess the efficacy of oral beta blockage treatment in primary (before established) and secondary (in threshold stages) prevention of severe retinopathy of prematurity (ROP) in premature infants born ≤32 weeks gestational age. Study design Following the PRISMA guidelines, published literature was systematically assessed up to April 27, 2018. Trials and observational studies, in which beta blockage was used to prevent severe ROP (defined as stage ≥3, or requiring treatment) were included. Meta-analyses including random effects models were conducted to determine the overall effect of oral beta blockage on prevention of ROP. Results Six studies (five clinical trials and one observational study) including 461 infants met inclusion criteria using propranolol. The pooled relative risk (RR) of severe ROP in the primary and secondary prophylaxis groups were 0.65 (95% CI 0.43–0.98, NNT = 7) and 0.48 (95% CI 0.35–0.65, NNT = 6) in RCTs, respectively. The RR of severe ROP in one observational study was 0.21 (95% CI 0.08–0.55) with a NNT of 3. There were low heterogeneity and publication bias. Side effects occurred in 8.4% of participants on propranolol. Conclusions Systematic assessment of studies showed that prophylactic oral propranolol appeared to be effective in preventing severe ROP in premature infants ≤32 weeks gestational age. Additional well powered, multinational, randomized control trials reporting on long-term outcomes are needed.Keywords
This publication has 27 references indexed in Scilit:
- Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in miceExperimental Eye Research, 2013
- Propranolol Inhibition of β-Adrenergic Receptor Does Not Suppress Pathologic Neovascularization in Oxygen-Induced RetinopathyInvestigative Ophthalmology & Visual Science, 2012
- The Levels of Evidence and Their Role in Evidence-Based MedicinePlastic and Reconstructive Surgery, 2011
- On the use of antiangiogenetic medications for retinopathy of prematurityActa Paediatrica, 2011
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityNew England Journal of Medicine, 2011
- Role of the Adrenergic System in a Mouse Model of Oxygen-Induced Retinopathy: Antiangiogenic Effects of β-Adrenoreceptor BlockadeInvestigative Ophthalmology & Visual Science, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009
- The International Classification of Retinopathy of Prematurity RevisitedArchives of Ophthalmology (1950), 2005
- Pathogenesis of retinopathy of prematurityGrowth Hormone & IGF Research, 2004
- Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of PrematurityArchives of Ophthalmology (1950), 1996